Shares of Dr Reddy's Laboratories today rose almost 3 per cent after the company inked a pact with UCB India for distribution and co-promotion of an epilepsy drug in the country.
The Hyderabad-based company's share closed at Rs 2,329.80 after gaining 2.80 per cent. In intra day, it had surged over 3 per cent to touch a high of Rs 2,335.
Similarly on NSE, the stock climbed as much as 2.69 per cent to end at Rs 2,330.10. During the trading session, the stock had touched a high Rs 2,335 and a low of Rs 2,281.95.
In terms of volume, 61,000 shares were traded on BSE and nearly 7.30 lakh shares changed hands on NSE.
In a BSE filling, Dr Reddy's Labs today said it has entered into an agreement with pharma firm UCB India for distribution and co-promotion of Briviact, used for treatment of epilepsy in India.
Briviact (brivaracetam) is approved as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients who are 16 years of age and older.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.